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posttransplant hospital stay.
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r Vaughn A. Starnes (Los Angeles, Calif). Dr Morales and
ssociates are to be congratulated on an excellent paper retrospec-
ively reviewing 21 years of experience at the TCH. During that
ime, they performed 165 transplants on 155 recipients. As noted
n the paper, children with cardiomyopathy made up more than
0% of the patients, another approximately 40% were children
ith CHD, and 7.9% were children with graft failure.
As noted by the author, this series compares favorably with the
nternational Registry of Heart and Lung Transplant survival sta-
istics and the causes for transplant.
As we see in this report, as also true of the registry, our
mprovement in survival over time has been primarily related to
ur early graft survival, particularly in the first year after the
ransplant event. As noted by these authors, an increase of 20%
ver this decade between 1995 and after 1995, it increased from
The Journal of ThoracicPPENDIX 1. Thirty-two variables analyzed to determine
isk factors for mortality and definitions
atient variables (n  16)
thnicity
African American
White
Hispanic
ra
Early era November 1, 1984-June 30,
1995
ge
Age  1 year old
11  age  20 years old
ex
Female
iagnosis
Congenital heart disease
Hypoplastic left heart syndrome
Failing Fontan circulation
ody surface area (m2)* ([Height (cm)  Weight
(kg)]/3600)1/2
npatient Hospital admission  24
hours before transplant
enal insufficiency† Requiring dialysis
notropic support†
ntubation†
echanical circulatory support†
onor variables (n  4)
old ischemic time*
onor age*
onor/recipient weight ratio*
ositive cross-match
ntraop and postop variables (n  12)
ardiopulmonary bypass time*
oncomitant complex pulmonary
artery reconstruction
oncomitant aortic arch
reconstruction
rior systemic–pulmonary artery
shunt
e-sternotomy
enal insufficiency‡ Requiring dialysis
rolonged intubation‡  5 cumulative days of
intubation
echanical circulatory support‡
rrhythmia Recurrent and/or requiring
treatment
eceiving blood products Any blood product during
intensive care unit stay
nfection Positive culture and
antibiotic treatment
nhaled nitric oxide therapy‡
Analyzed as continuous variable. †Up until time of transplant. ‡Duringand Cardiovascular Surgery ● Volume 133, Number 3 637
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D1% to 91% during that period of time; that survival statistic
aralleled the course over the next 5 to 10 years.
The authors bring up some interesting findings that are also true
n the registry, that ethnicity does affect survival, with the pediatric
hite population faring better than the African American or His-
anic transplant recipients.
The other interesting factor was that the mismatch between
enders was very compelling. The mismatch of a male recipient
eceiving a female donor heart had a significant importance over
ime and, in fact, at 10 years the survival difference was 49%
ersus 70%. I thought that was a very compelling argument about
rying to match gender.
I have three questions.
The ISHLT reported a significant negative impact with an odds
atio of 2.1 on the influence of CHD as a pretransplant diagnosis
n the outcome of the recipient. You found no statistical difference
etween the cardiomyopathy group and the CHD group. Could you
xplain that?
Dr Morales. I think if we look into the two different eras, in the
re-1995 era it was a risk factor. In the post-1995 era, in which we
ow have a dedicated congenital heart surgery center, including
urgeons, anesthesiologists, and intensivists, CHD is no longer a
isk factor because of the large improvement in early survival. I
elieve that this is why, overall, it did not come out as a risk factor
n our analysis.
Dr Starnes. My second question concerns the negative impact
f prolonged intubation. With your odds ratios on 1- and 5-year
urvivals (7.4 and 3.8, respectively) as a negative impact of this
actor, I would view this more as a surrogate for a very sick
retransplant patient with other comorbidities. Are you suggesting
hat intubation is an independent risk factor outside of the comor-
idities that might go along with that?
Dr Morales. I agree with you that it probably has something to
o with their pretransplant status; however, the statistical analysis
ould say that prolonged intubation is itself an independent risk
actor for mortality.
Dr Starnes. Again, regrettably, the long-term outcome has
emained the same over the past 20 years, and the survival beyond
years is still affected by coronary artery disease, with death due
o coronary disease representing 30% to 35% in most series and
4% in your series. Given this, has your group taken on any novel
mmunosuppressive approaches? I noted in your manuscript that
ome 5% of your patients were receiving rapamycin.
Dr Morales. When a patient has transplant artery coronary
isease, one thing that we have changed in the past 5 to 8 years is
rescribing rapamycin. Almost all of our applications of rapamy-
in are for transplant coronary disease. We have also started
rescribing pravastatin (Pravachol) as possible prophylaxis against
ransplant coronary disease once the patients reach adolescence.
Dr Roland Hetzer (Berlin, Germany). I want to congratulate
he Houston group for this enormous experience. Our own activ-
ties among more than 1500 heart transplants include 140 infants
nd children under the age of 18 years during the past 20 years.
ur 10-year survival in this transplanted group was 70%. We have
ttributed this to very close, meticulous monitoring of rejection by
lectrophysiologic telemetric methods.
I would like you to comment on several issues: the mode of
ejection monitoring in children and infants, the impact of chronic i
38 The Journal of Thoracic and Cardiovascular Surgery ● Marcenal failure at long term, the obvious lack of compliance in
dolescents, and the diagnostics of transplant vasculopathy, which
e have found to be an important factor for survival beyond 10
ears after transplantation.
Dr Morales. In terms of how we monitor these children for
hronic rejection or acute rejection, we do myocardial biopsies
very 2 weeks during the first 3 months, then every 3 months for
he first year, then every 6 months for the next 4 years, and yearly
hereafter. Our cardiology colleagues also do a great job at clini-
ally following these children quite frequently and often will
iagnose a change in their clinical status. At 3 months, we do
oronary angiography as a baseline and then follow that up with
early angiograms to diagnose coronary disease.
Renal failure played a significant cause in only 1 of the 59
eaths in this series, so it actually has not played a major role in
ur series in regard to mortality. However, it certainly is a widely
nown morbidity in these patients, whose renal function we follow
losely. Two of our patients have required renal transplant.
Adolescent noncompliance has always been a problem, and as
ou have seen in our slide on conditional 5-year survival, it
efinitely has a negative impact on late survival. As do most
rograms, we pride ourselves in developing close and strong
elationships with our patients, so through our counseling we try to
mprove compliance.
Dr Cooley. In that initial operation that we did on an 8-month-
ld infant, our concern was, then, about the possibility of the
nfluence of immunosuppressive drugs on growth and develop-
ent. It was very gratifying to see how that little girl grew and
ecame intelligent; she was a good student in school and so forth.
t was a real tragedy when she did pass away from coronary
cclusive changes.
I missed it in the donors involved. The situation with the donor
n our first transplant was rather complex. The donor was another
nfant from Dallas, Texas. The mother and father, in a fit of anger,
ad thrown the child out of a second-story window and the child
ustained severe brain injury. To get the permission for the dona-
ion, we had to go to the jail in Dallas where the mother and father
ere incarcerated. We brought the baby down to Houston and had
he little recipient available. The recipient was an adopted child. So
he situation became rather complicated.
I missed it in your policy now at TCH about ABO mismatch in
andidates for transplantation. I hear reports of other institutions
hat are using ABO mismatch. What is the policy at the Children’s
ospital in Houston?
Dr Morales. Thank you, Dr Cooley, for your comments. It is
uite an honor to have you here at this presentation to give all of
s perspective on this field. I am aware that Toronto has had good
uccess with the ABO mismatch. However, we have not performed
ny ABO mismatch transplants at TCH. It is something that our
ardiologists are interested in and they have been investigating this
ption, but as of this time we have not applied this donor man-
gement strategy.
Dr Lucio Parenzan (Bergamo, Italy). To find a small heart, as
ou know, is difficult. Many times you have to fly many hours.
hat do you think about the new system they have in Germany
here they are perfusing the heart during the transplantation? Do
ou have any data? Do you have any knowledge? Do you think it
s a good idea?
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I can say that we did analyze ischemic time, with maximum
schemic time being 7.5 hours, as a continuous variable to see
hether it was a risk factor for mortality. Our analysis demon-
trated that at no time was ischemic time a risk factor for death.
owever, having said that, there obviously is an ischemic time in
hich graft function and mortality would be affected negatively,
ut it is unclear to me that it is at 4 hours, as we have always been
aught.
Dr Adnan Cobanoglu (Cleveland, Ohio). I would like to find
ut more about the retransplants. There were 13 patients. How was
he outcome in the retransplantation group?
Dr Morales. We calculated Kaplan–Meier survival curves of
he 13 retransplants and of all the primary grafts, and we comparedThe Journal of Thoracicohorts. However, I do not know how much can be gathered from
hat analysis, since there were only 13 retransplants. Having said
hat, our belief now is that their survival is about the same, but we
ill have to see whether that is true as our numbers and length of
ollow-up increase.
Dr William A. Baumgartner (Baltimore, Md). You said isch-
mic time is not related to rejection or survival. Increasing evi-
ence suggests that there is a relationship between ischemic time,
r injury at the time of procurement, and the future development of
oronary artery disease. Have you looked at this correlation?
Dr Morales. We did not look at the issue of ischemic time and
hronic rejection in particular. We did show that, at least in our
eries, ischemic time was not related to death or graft failure in
eneral. This issue of ischemic time and chronic rejection is anCH
Dhe two groups. We did not find a statistical difference between the interesting one that we should investigate in our series.and Cardiovascular Surgery ● Volume 133, Number 3 639
